Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab

Clinical trial NCT02926196 · COMPLETED

Trial details

NCT number: NCT02926196
Sponsor: Istituto Oncologico Veneto IRCCS
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Triple Negative Breast Neoplasms

Start date: 2016-06-17
Primary completion: 2024-06-01
Enrollment: 474

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.